Impact of Dormant Cancer Cells on the Brain Microenvironment


2023 Emerging Leader Award

Jose Javier Bravo-Cordero, PhD, Icahn School of Medicine at Mount Sinai

Jose Javier Bravo-Cordero, PhD

Dr. Bravo-Cordero is taking advantage of high-resolution imaging technology to understand how dormant cancer cells instruct neuronal tissue at the single cell level. By combining in vitro co-culture systems of tumor/brain cells and organotypic cultures, he will define the molecular mechanisms governing niche adaptation by dormant cells in the brain. The work proposed will generate insights that will directly impact future treatment of brain metastases.

Dr. Bravo-Cordero received his bachelor’s degree in biology from the Autonoma University of Madrid and his PhD from the Spanish National Cancer Institute (CNIO) in Madrid, Spain. He completed his postdoctoral research work at the Albert Einstein College of Medicine in New York. Dr. Bravo-Cordero is currently an Associate Professor at the Icahn School of Medicine at Mount Sinai Hospital, in the Department of Medicine and the Tisch Cancer Institute in New York. His lab studies the mechanisms that regulate metastasis and tumor dormancy, and the interplay with the microenvironment by applying high-resolution imaging technologies.

published research

Mukherjee A, Bravo-Cordero JJ. Regulation of dormancy during tumor dissemination: the role of the ECM. Cancer Metastasis Rev. 2023.

Wan Y, Cohen J, Szenk M, Farquhar KS, Coraci D, Krzysztoń R, Azukas J, Van Nest N, Smashnov A, Chern YJ, De Martino D, Nguyen LC, Bien H, Bravo-Cordero JJ, Chan CH, Rosner MR, Balázsi G. Nonmonotone invasion landscape by noise-aware control of metastasis activator levels. Nat Chem Biol. 2023.

Maurin M, Ranjouri M, Megino-Luque C, Newberg JY, Du D, Martin K, Miner RE 3rd, Prater MS, Wee DKB, Centeno B, Pruett-Miller SM, Stewart P, Fleming JB, Yu X, Bravo-Cordero JJ, Guccione E, Black MA, Mann KM. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. Nat Commun. 2023.

BACK TO OUR PORTFOLIO